Skip to content

Study · Non-randomized trial · n = 27 · 1996

10 results

The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome.

Cotterill AM, McKenna WJ, Brady AF, Sharland M, Elsawi M, Yamada M, Camacho-Hübner C, Kelnar CJ, Dunger DB, Patton MA, Savage MO

The Journal of clinical endocrinology and metabolism1 Jun 1996Cited by 54 (Europe PMC)

PMID8964866 (opens in a new tab)DOI10.1210/jcem.81.6.8964866 (opens in a new tab)PepBankPUB-08964866
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, rhGH increased height SD score from -3.01 +/- 0.10 to -2.36 +/- 0.10 (P < 0.0001).

    In plain wordsIn children with Noonan's syndrome, height SD score increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SD score
    Study

    n = 27

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Height SD score
    −3.01 SD score
    rhGH group, baseline
    Height SD score
    −2.36 SD score
    rhGH group, after 12 months

    Source sentences

    Summary
    Height SD score increased from -3.01 +/- 0.10 to -2.36 +/- 0.10 (P < 0.0001) after 12 months; height velocity (HV) increased from 4.9 +/- 0.2 to 8.9 +/- 0.3 cm/yr at 6 months and 8.1 +/- 0.4 cm/yr (P < 0.0001) from 6-12 months.
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  2. 02HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, rhGH increased height velocity from 4.9 +/- 0.2 to 8.9 +/- 0.3 cm/yr at 6 months.

    In plain wordsIn children with Noonan's syndrome, height velocity increased during rhGH treatment at 6 months.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight velocity at 6 months
    Study

    n = 27

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 6 monthsAs given in this study (human).

    Measurements

    Height velocity
    4.9 cm/yr
    rhGH group, baseline
    Height velocity
    8.9 cm/yr
    rhGH group, at 6 months

    Source sentences

    Summary
    Height SD score increased from -3.01 +/- 0.10 to -2.36 +/- 0.10 (P < 0.0001) after 12 months; height velocity (HV) increased from 4.9 +/- 0.2 to 8.9 +/- 0.3 cm/yr at 6 months and 8.1 +/- 0.4 cm/yr (P < 0.0001) from 6-12 months.
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  3. 03HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, height velocity reached 8.1 +/- 0.4 cm/yr from 6-12 months (P < 0.0001).

    In plain wordsIn children with Noonan's syndrome, height velocity increased during rhGH treatment from 6-12 months.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight velocity at 6-12 months
    Study

    n = 27

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Height velocity
    4.9 cm/yr
    rhGH group, baseline
    Height velocity
    8.1 cm/yr
    rhGH group, 6-12 months

    Source sentences

    Summary
    Height SD score increased from -3.01 +/- 0.10 to -2.36 +/- 0.10 (P < 0.0001) after 12 months; height velocity (HV) increased from 4.9 +/- 0.2 to 8.9 +/- 0.3 cm/yr at 6 months and 8.1 +/- 0.4 cm/yr (P < 0.0001) from 6-12 months.
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  4. 04HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, rhGH increased height velocity SD score from -0.7 +/- 0.15 to +2.42 +/- 0.32 (P < 0.0001).

    In plain wordsIn children with Noonan's syndrome, height velocity SD score increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight velocity SD score
    Study

    n = 27

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Height velocity SD score
    −0.7 SD score
    rhGH group, baseline
    Height velocity SD score
    2.42 SD score
    rhGH group, over 12 months

    Source sentences

    Summary
    The HV SD score increased from -0.7 +/- 0.15 to +2.42 +/- 0.32 over 12 months (P < 0.0001).
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  5. 05HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, height velocity increased by more than 2 cm/yr in 24 patients during rhGH treatment.

    In plain wordsIn children with Noonan's syndrome, 24 patients gained more than 2 cm/yr in height velocity during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight velocity response
    Study

    n = 27

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Patients with height velocity increase of more than 2 cm/yr
    24 patients
    rhGH-treated children

    Source sentences

    Summary
    The increase in HV was more than 2 cm/yr in 24 patients.
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  6. 06HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, rhGH increased IGF-I from 121 +/- 13 to 240 +/- 22 micrograms/L (P < 0.0001).

    In plain wordsIn children with Noonan's syndrome, IGF-I increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-I
    Study

    n = 27

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    IGF-I
    121 micrograms/L
    rhGH group, baseline
    IGF-I
    240 micrograms/L
    rhGH group, at 12 months

    Source sentences

    Summary
    IGF-I increased from 121 +/- 13 to 240 +/- 22 micrograms/L at 12 months (P < 0.0001), and IGF-binding protein-3 increased from 2.65 +/- 0.20 to 4.01 +/- 0.42 mg/L at 12 months (P = 0.0009).
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  7. 07HumanNon-randomized trialEfficacy outcome

    In children with Noonan's syndrome, rhGH increased IGF-binding protein-3 from 2.65 +/- 0.20 to 4.01 +/- 0.42 mg/L (P = 0.0009).

    In plain wordsIn children with Noonan's syndrome, IGF-binding protein-3 increased during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseIGF-binding protein-3
    Study

    n = 27

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    IGF-binding protein-3
    2.65 mg/L
    rhGH group, baseline
    IGF-binding protein-3
    4.01 mg/L
    rhGH group, at 12 months

    Source sentences

    Summary
    IGF-I increased from 121 +/- 13 to 240 +/- 22 micrograms/L at 12 months (P < 0.0001), and IGF-binding protein-3 increased from 2.65 +/- 0.20 to 4.01 +/- 0.42 mg/L at 12 months (P = 0.0009).
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  8. 08HumanNon-randomized trialSafety outcome

    In treated children with Noonan's syndrome, mean maximal LV wall thickness did not increase, reaching 0.63 +/- 0.02 cm at the mitral valve.

    In plain wordsIn children with Noonan's syndrome, heart wall thickness at the mitral valve did not increase during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeLV wall thickness at mitral valve
    Study

    n = 27

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Maximal LV wall thickness at mitral valve level
    0.63 cm
    rhGH group, 12 month value
    Maximal LV wall thickness at mitral valve level
    0.63 cm
    comparison group

    Source sentences

    Summary
    There was no increase in mean maximal LV wall thickness during the study in either the treatment group (12 month values were 0.63 +/- 0.02 cm at the mitral valve level and 0.66 +/- 0.02 cm at the papillary muscle level) or in the comparison group (0.63 +/- 0.04 cm at the mitral valve level and 0.61…
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  9. 09HumanNon-randomized trialSafety outcome

    In treated children with Noonan's syndrome, mean maximal LV wall thickness did not increase, reaching 0.66 +/- 0.02 cm at the papillary muscle.

    In plain wordsIn children with Noonan's syndrome, heart wall thickness at the papillary muscle did not increase during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeLV wall thickness at papillary muscle
    Study

    n = 27

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Measurements

    Maximal LV wall thickness at papillary muscle level
    0.66 cm
    rhGH group, 12 month value
    Maximal LV wall thickness at papillary muscle level
    0.61 cm
    comparison group

    Source sentences

    Summary
    There was no increase in mean maximal LV wall thickness during the study in either the treatment group (12 month values were 0.63 +/- 0.02 cm at the mitral valve level and 0.66 +/- 0.02 cm at the papillary muscle level) or in the comparison group (0.63 +/- 0.04 cm at the mitral valve level and 0.61…
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.
  10. 10HumanNon-randomized trialSafety outcome

    In children with Noonan's syndrome, no patient developed features of hypertrophic cardiomyopathy during rhGH treatment.

    In plain wordsIn children with Noonan's syndrome, no patient developed features of hypertrophic cardiomyopathy during rhGH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableHypertrophic cardiomyopathy
    Study

    n = 27

    Outcome group
    Adverse events · Cardiovascular
    Studied dose
    4 IU/m2.day · subcutaneous · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Abnormal anabolic effects of rhGH on myocardial thickness were not confirmed, and no patient developed features of hypertrophic cardiomyopathy.
    2 context sentences
    Summary · context
    We report a multicenter study examining the efficacy and safety of rhGH (4 IU/m2.day, sc) in children with NS.
    Summary · context
    In the treatment group, 27 subjects completed 12 months of therapy.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.